# Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC)

> **NCT02681549** · PHASE2 · COMPLETED · sponsor: **Yale University** · enrollment: 41 (actual)

## Conditions studied

- Melanoma
- Non-small Cell Lung Cancer
- Brain Metastasis

## Interventions

- **DRUG:** Pembrolizumab plus Bevacizumab

## Key facts

- **NCT ID:** NCT02681549
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-01
- **Primary completion:** 2024-09-11
- **Final completion:** 2025-03-31
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2025-08-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02681549

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02681549, "Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02681549. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*